Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jambone E is a phenolipid compound isolated from the fruit tree Syzygium jambos and also present in Syzygium cumini. It has demonstrated potential antidiabetic activity in vitro and in vivo, including enhanced glucose consumption, increased glycogen synthesis, and suppression of gluconeogenesis in insulin-resistant hepatocytes and diabetic mouse models. Mechanistically, jambone E acts mainly by activating the AKT-mediated insulin signaling pathway, resulting in upregulation of AKT phosphorylation and modulation of related metabolic gene expression. Jambone E also exhibits weak antioxidant activity and is a member of the broader class of phloroglucinol derivatives isolated from Syzygium species. The compound is being investigated for its utility in the management of metabolic diseases such as diabetes mellitus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jambone E.